SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is seeing increased market attention as community members debate its long-term potential as essential infrastructure for real-world assets and AI integration. While some investors are actively accumulating, others are expressing frustration over stagnant price action and are waiting for legislative developments to serve as a catalyst for growth.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

The SGOV ETF is trending as investors park capital in short-term U.S. Treasuries to navigate market volatility and secure yield while awaiting clearer economic signals. Community discussion centers on using the fund as a defensive 'parking spot' to preserve principal and generate steady monthly income amidst ongoing concerns regarding inflation, debt levels, and recession risks.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania Trump meme coin is trending as a flashpoint for community debate, with participants actively discussing allegations that the token and related assets are part of a broader pump-and-dump scheme orchestrated by political figures. Investors are currently expressing intense frustration over significant portfolio losses, while skepticism regarding the token's legitimacy and long-term viability continues to dominate the discourse.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

CHPY is drawing significant attention from income-focused investors who favor its unique strategy of holding physical semiconductor stocks, which distinguishes it from many other YieldMax ETFs that rely solely on synthetic derivatives. While the semiconductor sector has experienced recent volatility, community members are actively debating the merits of long-term holding versus tactical rotation to manage NAV fluctuation, with many viewing the weekly distributions as a sustainable way to build passive income during market cycles.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently driven by heightened investor enthusiasm following positive analyst coverage that highlights its potential to evolve into a large-cap biotech entity. The community is actively debating the clinical prospects of soquelitinib, with many focusing on its competitive advantage as an oral treatment against current injectable standards while closely monitoring short interest and upcoming trial data presentations.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley is trending as investors react to its recent workforce restructuring and the firm's strategic focus on expanding its crypto and digital asset footprint. The community is actively discussing the bank's role in high-profile IPO pipeline developments and evaluating its resilience against broader private credit liquidity concerns.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Magnificent Seven ETF ($MAGS) is trending as investors grapple with shifting sentiment regarding AI-driven capital expenditure and valuation concerns, with community members actively debating whether the recent price consolidation represents a healthy rotation or a more significant structural breakdown. Market participants are closely watching key technical support levels and earnings reports to determine if mega-cap tech leadership can regain its footing or if the broader market will continue to rotate into cyclical sectors and semiconductors.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors debate the impact of its recent SuperApp launch and ongoing enterprise integrations, with the community split between those aggressively accumulating on dips and others expressing frustration over stagnant price action and the project's long-term utility. Market participants are closely watching for legislative developments like the Clarity Act and proof of sustained payroll volume as key catalysts to validate the project's real-world payment infrastructure.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending as traders analyze its price consolidation and long-term utility within the expanding AI agent and tokenization ecosystem. The community remains focused on potential institutional adoption and regulatory catalysts while debating whether current levels offer a strategic accumulation opportunity.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The Bitwise XRP ETF is trending as investors debate XRP's long-term utility versus its sensitivity to broader crypto liquidity and regulatory developments. While some community members remain bullish on institutional adoption and cross-border payment potential, others are actively tracking recent price volatility, network activity divergences, and the ongoing legislative progress of the Clarity Act.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?

Key PointsCOO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share...

Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss

Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) has been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a s...

Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near

Key PointsA major owner of Rapport Therapeutics reported selling 426,005 shares for a total value of approximately $17.18 million on April 17, 2026...

BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP)

BTIG Research restated a "buy" rating and issued a $53.00 target price on shares of Rapport Therapeutics in a research note on Wednesday...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 20,225 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the transaction, the...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) major shareholder Rock Ventures L.P. Third sold 426,005 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The...

Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of the company's stock in a transaction on Friday, April 17th. The stock was sold at an average price of $39.99, for a total transaction of $808,797.75. Following the completion of the...

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2% - Here's What Happened

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2% - Time to Sell...

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened

Equity

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.21	--	--	N/A
Q2 '26	-$1.18	-$1.19	-1.14%	MISSED
Q1 '26	-$0.62	-$0.42	32.70%	BEAT
Q4 '25	-$0.68	-$0.72	-6.28%	MISSED
Q3 '25	-$0.78	-$0.71	8.39%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings